Parcel Bio
Synthetic biology for RNA medicines
About
Founded in 2023 by David Weinberg and Chris Carlson, Parcel Bio develops next-generation RNA medicines using synthetic biology and molecular engineering. The company targets complex diseases including oncology and autoimmune disorders, collaborating with biotech and pharmaceutical partners to advance RNA-based therapeutic modalities and delivery technologies. Parcel Bio raised $13.2M in seed funding in 2026, backed by investors like Y Combinator and Ritual Capital, fueling research and development towards innovative genetic medicines.
Products
-
RNA Medicines Platform
— Develops synthetic biology-based RNA therapeutics targeting oncology and autoimmune diseases
Customer sectors: biotech, pharmaceutical
Market research & competitive positioning
Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for Parcel Bio — available to members.
Related Companies
Other startups in Biotech & Therapeutics
